Five academicians talk about tumor prevention and control! The frontier breakthrough and the progress are here.

(Health Times reporter Jing Chao Huang Lanjun) May 10-12, by Shandong Cancer Center, Shandong Province Anti-Cancer Association, Shandong Cancer Hospital hosted by the "7th Shandong Province Cancer Conference" held in Jinan. More than 2000 cancer diagnosis and treatment, prevention and research workers attended the conference to discuss new progress in cancer prevention and treatment. Five Chinese Academy of Engineering academicians attended the conference and discussed the current breakthroughs and progress in cancer prevention and treatment from radiotherapy, endoscopy, precision medicine and surgery.
"radiotherapy plus", a new breakthrough in cancer treatment
Chinese Academy of Engineering, Shandong Province Cancer Hospital President Yu Jinming
WHO data released by the study, surgery, radiotherapy and chemotherapy in the contribution of tumor cure rate, surgery accounted for 22%, radiotherapy accounted for 18%, chemotherapy accounted for 5%; More than 60 percent of cancer patients in the United States receive radiation therapy, compared with less than 20 percent in China, and most radiotherapy is concentrated in major cities.
when more and more people began to pay attention to "precision medicine", in fact, radiotherapy has been ahead of the curve. Yu Jinming, a member of the Chinese Academy of Engineering and director of Shandong Cancer Hospital, said that in recent years, with the help of computer technology and medical imaging technology, the treatment position is more accurate, the radiation dose is more accurate, and can achieve the balance of maximizing the elimination of tumor tissue and protecting the minimization of damage to healthy tissue. From the discovery of cobalt 60 to the application of accelerators, to today's proton radiotherapy, CT-guided decentralized treatment, the area of irradiation is more accurate, some internal irradiation can even go directly to the tumor site, reducing damage to normal tissue.
Yu Jinming believes that with the continuous development of research, the "radiotherapy plus" model will be more and more recognized, radiotherapy and precision medicine, radiotherapy plus artificial intelligence, radiotherapy plus immunotherapy are the future direction. The "radiotherapy and immunity" treatment model will stimulate a series of molecular biological effects, which will hopefully bring a real breakthrough in tumor treatment.
"endoscope s", a new idea of cancer prevention and control
Chinese Academy of Engineering, Changhai Hospital digestive medicine director Li Zhaoshen
"50% of the world's digestive tract tumors occur in China, 50% of people died of gastrointestinal tumors, is Chinese." "Li Zhaoshen, a member of the Chinese Academy of Engineering, stressed at the conference that the prevention and control of digestive tract cancer should be advanced as early as possible, one is to raise the awareness of the people's early diagnosis and treatment, and the other is to promote comfortable screening, no longer let the public's fear of endoscopy become a roadblock to the prevention and control of gastrointestinal tumors." People under 50 years of age should have a gastroscopy and go over 50 years old to have a gastroscopy.
in Li Zhaoshen's view, endoscopy should be used for early diagnosis, not just for late treatment. In order to allow more people to undergo painless endoscopy, Li Zhaoshen led the development of capsule gastroscopy, just like taking capsule drugs, drinking water to swallow the size of the endoscopy robot, 15 minutes can complete the endoscopy.
it is known that endoscopy ultrasound (EUS) is the high-frequency ultrasound lens placed on the top of the endoscopy, in the digestive tract endoscopy at the same time to obtain high-resolution images of the digestive tract and surrounding organs. According to Li Zhaoshen, the research and development of remote-controlled capsule gastroscopes, esophageal capsule endoscopy research and development have achieved good results, in addition to they will also endoscopy and radiotherapy combined.
, for example, the endoscopic research that their team is doing on pancreatic tumors. "First mark the pancreatic tumor, like a radar sweep, set the scope, and then put some radiation through an ultrasound endoscope through a special pathway in the tumor for close-range radiation therapy."
"surgery plus", the most preferred treatment of liver cancer
Chinese Academy of Engineering, Tsinghua Changxuan Hospital Executive Director Dong Jiahong
primary liver cancer is one of the most common and malignant tumors, in the world, each year, there are more than 841,000 new cases of liver cancer. China accounts for about 50% of the world's new cases of liver cancer each year, with the incidence of malignant tumors being the fourth highest. In recent years, the cause of liver cancer in China rose from 3rd to 2nd in malignant tumors.
Dong Jiahong, a member of the Chinese Academy of Engineering and executive director of Tsinghua Changxuan Hospital, said that only 20% of the first-time confirmed liver cancer patients in China can receive surgery and other treatment, and more than 80% of patients are already in the advanced stage once found.
surgery is still the preferred treatment for liver cancer, but because most liver cancer patients have cirrhosis, or at the time of diagnosis, most of the patients are in the middle and late stage, the opportunity to get surgical removal of about 20%-30%. Dong Jiahong stressed that "the treatment of advanced liver cancer is very rapid, new chemotherapy, targeted treatment, immunotherapy and traditional surgery, radiotherapy, interventional therapy organic combination, to improve the overall treatment of liver cancer patients, and even get the opportunity to cure."
at present, the treatment of liver cancer can be divided into local treatment and systemic treatment. Local treatment mainly includes surgery, hepatic artery embolism chemotherapy, transdermal radiofrequency ablation therapy, radiation therapy, etc.
Dong Jiahong academician introduced that in recent years, with the increasing treatment of liver cancer, precision surgical treatment combined with systemic targeted treatment and immunotherapy, for patients to carry out personalized combination therapy, so that the effectiveness of advanced liver cancer treatment greatly improved.
"drug plus", tumor drug-selecting individualization
Chinese Academy of Engineering, Central South University Xiangya Hospital Clinical Pharmacological Research Institute Director Zhou Hongxuan
in the game with the tumor, surgery, radiotherapy, chemotherapy, drug treatment is often because of individual differences used as a combination of fists to fight. As a scientist who first put forward the theory of "human-based drug use, tailor-made clothing" in the 1990s, Zhou Hongxuan, a member of the Chinese Academy of Engineering and director of the Institute of Clinical Pharmacology at Xiangya Hospital of Central South University, said that the completion of the Human Genome Project has made us aware of the differences between individuals, although the proportion is small, and the individual differences in the efficacy of a single drug is due to the 3 million base differences in each person's genes.
for example, it is not good in the treatment of lung cancer, but in the EGFR gene mutation of lung cancer patients, the effect is very good, in the clinical use of this extremely expensive drug (about 160,000 yuan per course, a course of treatment for one month), must detect the EGFR gene mutation. In addition, each year the FDA approves a number of subgroups or various targets for certain diseases on the market, China's lung cancer biomarker corresponding target drugs are also more aware of than other cancers.
in order to help first-time patients choose treatment drugs more efficiently and quickly, Professor Zhou Hongxuan developed a high-throughput individualized genetic testing project covering high-risk cancerininic disease in China. The project includes two aspects, one targeting drug-related genes, covering 59 common tumor mutation genes, 36 targeted drug-related genes entering clinical trials, and more than 3,600 hot-spot mutations covering more than 200 drugs undergoing clinical trials, and chemotherapy-related genes, including 14 drug metabolism and transport-related genes and more than 40 mutation sites.
the "tumor plus", concerned about the cardiovascular
of patients with tumors, Chinese Academy of Engineering, Shandong University Qilu Hospital cardiology director Zhang Yun
cardiovascular disease and tumor is the most common cause of death in China's residents, and cardiovascular disease is one of the main causes of death in tumor patients. Zhang Yun, a member of the Chinese Academy of Engineering and director of cardiology at Qilu Hospital of Shandong University, pointed out that there are common risk factors for tumors and cardiovascular diseases, and that some common risk factors for heart disease are often high-risk factors for tumors. On the other hand, tumor therapy can induce or aggravate cardiovascular damage.
but tumor cardiology is still in its infancy in China, first of all, the concept of oncology and cardiovascular doctors changed. Originally more is "talking about cancer color change", treatment to take limited treatment, the future should be in the treatment of tumors at the same time to give the whole heart protection. Oncologists act as the intake of treatment, and cardiovascular physicians act as part of the problem.
According to Zhang Yun, at this stage, the tumor cardiology unit in China has five clinical forms, namely: cardiology department of the oncology hospital;
it is understood that this meeting has a main venue, 26 sub-venues, invited a number of domestic and foreign experts in the field of cancer to make academic reports. Oncology medical workers from various cities in Shandong Province conduct extensive and in-depth academic exchanges and discussions on the basic research, prevention, diagnosis, treatment and rehabilitation of tumors.
.